TPCS:NASDAQTechPrecision Corporation Analysis
Data as of 2026-05-05 - not real-time
$4.17
Latest Price
8/10Risk
Risk Level: High
Executive Summary
TechPrecision Corp (TPCS) is trading at $4.17, just above its identified support of $2.95 and well below the 200‑day SMA of $4.55, indicating a price gap to its long‑term average. The 20‑day SMA ($3.85) sits above the 50‑day SMA ($3.64) and both are under the current price, while the MACD histogram is positive and the signal line is bullish, suggesting short‑term upward momentum. However, the RSI at 61.8 hints at a market that is approaching overbought territory and the 30‑day volatility of ~59% underscores a highly erratic price environment. Fundamentally, the company is distressed: revenue has contracted 6.9% YoY, gross margin is only 18%, operating margin is negative 19%, and net profit margin sits at –3.4% with a trailing EPS of –$0.12. The balance sheet shows a debt‑to‑equity ratio exceeding 130, total debt of $10.5 M versus a cash balance of merely $70 K, and free cash flow is deeply negative. Despite these challenges, the forward EPS of $1.58 translates to a forward P/E of 2.64, dramatically lower than the industry average of 31, and the current price‑to‑book of 5.2 is modest for a capital‑intensive sector. The market sentiment is in “Extreme Greed” mode (Fear‑Greed Index 90.68), which may be inflating the price despite the weak fundamentals. Investors should weigh the cheap valuation against the substantial operational and financial risks before committing capital.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bullish MACD and price above short‑term SMAs
- High short‑term volatility
- Weak earnings and negative cash flow
Medium Term
1–3 yearsNeutral
Model confidence: 4/10
Key Factors
- Potential earnings upside from forward EPS
- Continued debt burden and cash constraints
- Sector exposure to defense spending cycles
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Sustained negative margins and high leverage
- Lack of dividend and cash generation
- Risk of further price depreciation if turnaround stalls
Key Metrics & Analysis
Financial Health
Revenue Growth-6.90%
Profit Margin-3.43%
P/E Ratio2.6
ROE-14.09%
ROA-0.17%
Debt/Equity131.72
P/B Ratio5.2
Op. Cash Flow$143.0K
Free Cash Flow$-1831250
Industry P/E31.1
Technical Analysis
TrendNeutral
RSI61.8
Support$2.95
Resistance$4.69
MA 20$3.85
MA 50$3.64
MA 200$4.55
MACDBullish
VolumeStable
Fear & Greed Index90.68
Valuation
GradeUndervalued
TypeValue
Risk Assessment
Beta0.84
Volatility59.36%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.